Related Experiment Video
Updated: May 14, 2026
07:02
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
Published on: September 14, 2010
Mucosal Kaposi sarcoma, a Rare Cancer Network study
Juliette Thariat1, Youlia Kirova, Terence Sio
1Department of Radiation Oncology, Centre Laccasagne, Nice, France;
Rare Tumors
|February 2, 2013
Summary
This study on mucosal Kaposi's sarcoma (KS) found that low-dose radiotherapy is safe and effective for both HIV-positive and HIV-negative patients. Further research into systemic treatments alongside radiotherapy is recommended for head and neck cases to prevent distant relapses.
Area of Science:
- Oncology
- Radiation Oncology
- Infectious Diseases (HIV/AIDS)
Background:
- Mucosal Kaposi's sarcoma (KS) is rare, with limited literature on its management.
- This study focuses on the treatment and outcomes of mucosal KS across multiple institutions.
Purpose of the Study:
- To evaluate the safety and efficacy of treatments for mucosal Kaposi's sarcoma.
- To analyze survival rates and toxicity in patients with mucosal KS, considering HIV status.
Main Methods:
- Retrospective data collection from 15 patients with mucosal KS (stages I-II) treated between 1994-2008.
- Analysis included patients >16 years with >6 months follow-up, assessing radiotherapy (RT) and chemotherapy regimens.
- CD4 counts, disease stage, treatment modalities, survival, and toxicity were evaluated.
Main Results:
- Head and neck sites were most common (66%); 11 patients were HIV-positive.
- Radiotherapy was administered regardless of CD4 status, with a median dose of 16.2 Gy.
- Five-year disease-free survival was 81.6% with RT and 75.0% without RT. Toxicity was manageable (grade 1-2).
Conclusions:
- Low-dose radiotherapy is a safe and effective treatment for mucosal KS in both HIV-positive and HIV-negative individuals.
- Systemic treatments may be beneficial for head and neck mucosal KS to prevent distant relapses.
- Surgery can be considered for symptomatic lesions, with careful attention to bleeding risks.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...